Home Apoptosis p53 activator - E3 Ligase inhibitor RITA For research use only.

RITA

Synonyms: NSC 652287

RITA induces both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks, and also inhibits MDM2-p53 interaction by targeting p53.

RITA Chemical Structure

RITA Chemical Structure

CAS: 213261-59-7

Selleck's RITA has been cited by 11 Publications

1 Customer Review

Purity & Quality Control

Batch: S278101 DMSO] 58 mg/mL] false] Ethanol] 8 mg/mL] false] Water] Insoluble] false Purity: 99.93%
99.93

RITA Related Products

Signaling Pathway

p53 Signaling Pathways

p53 Signaling Pathway

Choose Selective p53 Inhibitors

Biological Activity

Description RITA induces both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks, and also inhibits MDM2-p53 interaction by targeting p53.
Features Inducer of DNA cross-links, not a DNA intercalator.
Targets
Mdm2 [1] p53 [3]
In vitro
In vitro RITA shows a highly selective pattern of differential cytotoxic activity in the tumor cell lines, due to cellular accumulation to the cytosolic (S100) fraction. RITA also inhibits the growth of other renal cell lines including ACHN and UO-31 with IC50 of 13 μM and 37 μM, respectively. [1] RITA (10 nM) causes cell cycle arrest with accumulation of cells at the G2-M phase and induces DNA fragmentation and apoptosis at 100 nM, both with evaluated p53 protein levels. RITA (30 nM) also induces both DNA-protein and DNA-DNA cross-links in A498 cells. Meanwhile RITA has no effects on top1-mediated relaxation of supercoiled SV40 DNA. [2] RITA significantly suppresses the growth of HCT116 cells (97%) but only slightly inhibits the growth of HCT116 TP53-/- cells (13%). RITA is much more efficient at growth suppression in wild-type p53-expressing tumor cell lines than in cell lines lacking p53 and those expressing mutant p53. RITA binds full-length p53 but not glutathione S-transferase (GST) protein or HDM-2 (a key regulator of p53 is strongly supported by the rescue of embryonic lethality of MDM2). RITA blocks p53−HDM-2 interaction and p53 ubiquitination. RITA substantially decreases the amount of HDM-2 that is co-precipitated with p53, although both proteins are upregulated. RITA prevents interactions between the purified GST-p53 and 6XHis-tagged His-HDM-2 proteins. [3] RITA is shown to induce apoptosis by promoting p53Ser46 phosphorylation. [4] RITA induces activation of p53 in conjunction with up-regulation of phosphorylated ASK-1, MKK-4 and c-Jun. RITA induces the activation of JNK signaling. [5] But On the contrary, another results by nuclear magnetic resonance (NMR) show that RITA does not block the formation of the complex between p53 (residues 1-312) and the N-terminal p53-binding domain of MDM2 (residues 1-118), which is highly probable that the binding of RITA requires native conformation of p53. [6]
Cell Research Cell lines HCT116 cells and HCT116 TP53-/- cells
Concentrations 0.1 nM - 1 mM, 10 mM stocked in DMSO
Incubation Time 48 hours
Method Examination to assess susceptibility of cells to RITA (0.1 nM - 1 mM) is done using the XTT assay. Cells are inoculated into 96-well flat-bottom plates at a density of 1500 cells per well and incubated for 24 hours at 37 °C in a humidified 5% CO2 5% air atmosphere. Serial concentrations of RITA in DMSO are added to the wells, and sensitivity is determined 48 hours after the addition of RIT
In Vivo
In vivo RITA is well tolerated in mice after intraperitoneal administration, with no observable weight loss at doses up to 10 mg/kg during 1 month. After five injections of 0.1 mg/kg of RITA, the growth of the HCT116 tumors is suppressed by 40%, without apparent effects on the HCT116 TP53-/- tumors. At a dose of 1 or 10 mg/kg, RITA shows strong antitumor activity. Five 1 mg/kg injections of RITA results in a more than twofold decrease in the growth rate of p53-positive xenografts without any effect on p53-null xenografts. HCT116 tumors are 90% smaller in mice treated with 10 mg/kg of RITA than in control untreated mice. RITA inhibits the tumor growth in a wild-type p53−dependent manner. [3]
Animal Research Animal Models SCID mice carrying HCT116 and HCT116 TP53-/- xenografts
Dosages 0.1 mg/kg, 1 mg/kg or 10 mg/kg
Administration Administered via i.v. or i.p.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05260203 Completed
Multiple Myeloma|Solitary Plasmacytoma|Amyloidosis|Chronic Myeloid Leukemia|Chronic Lymphocytic Leukemia|T Cell Non-Hodgkin Lymphoma|Lymphocytic Lymphoma|Hodgkin Lymphoma|B-cell Non Hodgkin Lymphoma|Acute Myeloid Leukemia|Myelodysplasia|Chronic Myeloproliferative Disorder|Treatment Adherence|Treatment Adherence and Compliance
Advice Pharma Group srl
 June 4 2022 Not Applicable
NCT05153551 Completed
Autism Spectrum Disorder
University of Michigan|Blue Cross Blue Shield of Michigan Foundation
 January 27 2022 Not Applicable
NCT03806127 Completed
Irritable Bowel Syndrome
Urovant Sciences GmbH
 December 31 2018 Phase 2
NCT00779025 Completed
Coitus
Johnson & Johnson Consumer and Personal Products Worldwide
 January 2008 Not Applicable

Chemical Information & Solubility

Molecular Weight 292.37 Formula

C14H12O3S2
CAS No. 213261-59-7 SDF Download RITA SDF
Smiles C1=C(SC(=C1)C2=CC=C(O2)C3=CC=C(S3)CO)CO
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 58 mg/mL ( (198.37 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 8 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy RITA | RITA supplier | purchase RITA | RITA cost | RITA manufacturer | order RITA | RITA distributor